Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209676 · ClinicalTrials.gov registry record · Early Phase 1
IMCgp100 in Advanced Unresectable Melanoma
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT01209676: Completed Early Phase 1 study, sponsored by University of Pennsylvania.
NCT01209676 is a Early Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209676, a Early Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with advanced unresectable melanoma to assess the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in the setting of advanced unresectable melanoma. Six patients will be enrolled to complete the study over approximately 12-15 months.
Interventions
- DRUG IMCgp100 injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209676
The ClinicalTrials.gov registry entry for NCT01209676 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMCgp100 injection is the first listed.
NCT01209676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209676 about?
NCT01209676 is a clinical study titled "IMCgp100 in Advanced Unresectable Melanoma". A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with advanced unresectable melanoma to assess the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in t...
What is the current status of trial NCT01209676?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2010-09.
What interventions are being tested in trial NCT01209676?
The interventions under investigation include: IMCgp100 injection (DRUG).
Who is sponsoring clinical trial NCT01209676?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.